Navigation Links
Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured''

CV; the remaining eight patients tested positive for HCV, at an average of two years following the completion of treatment. The study found that these eight patients exhibited no consistency in age, gender or HCV genotype, and it has not been determined if these patients experienced a relapse or if they were re-infected with HCV.

"We at Roche are proud to be able to offer some hepatitis C patients the prospect of such a positive outcome with our currently-available therapies, but we also recognize the urgent need to further improve response rates," said Tom Klein, Vice President, Hepatology, Roche. "In addition to ongoing research with PEGASYS, Roche has the most comprehensive pipeline in the area, with four compounds currently in human development that target the virus in a number of different ways. The development of R1626 and partnerships with InterMune, Maxygen and Pharmasset, all underscore our long-term commitment to finding effective new therapies with the goal of successfully treating more patients with chronic hepatitis C."

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS, are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Suggest that Pegasys May be an Option in Hepatitis C Patients Unable to Tolerate Peg-Intron
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
(Date:8/29/2014)... ROBLES, Calif. , Aug. 29, 2014  Pacific ... of its new website design . The main ... overhaul that showcases the company,s new services and content ... By implementing a new streamlined design, viewers can now ... metrics for health care practices and create a more ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
(Date:8/28/2014)... NEW YORK, Aug. 28, 2014 Reportlinker.com ... available in its catalogue: North America ... 2020 http://www.reportlinker.com/p02343466/North-America-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html ... Market Outlook to 2020 Summary GlobalData,s ... Devices Market Outlook to 2020", provides key market ...
Breaking Medicine Technology:PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 2North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 3North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 4North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 5North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 6North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 7North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 8North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 9North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 10North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 11North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 12North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 13North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 14North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 15North America Aesthetic Lasers and Energy Devices Market Outlook to 2020 16
... 21 Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: ... developing topically administered products using its proprietary transdermal delivery ... Ph.D. as Chief Executive Officer and President.  Dr. Bonfiglio ... of Directors. With over 27 years of ...
... Romark Laboratories, L.C. and Intercell AG ... clinical trials of Romark,s antiviral drug, nitazoxanide, ... C virus (HCV) vaccine, IC41, during the ... http://photos.prnewswire.com/prnh/20100201/FL47022LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100201/FL47022LOGO) ...
Cached Medicine Technology:Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President 2Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President 3Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 2Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 3Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 4Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C 5
(Date:8/30/2014)... Midland, TX (PRWEB) August 30, 2014 ... Quotes Pros company to introduce better prices to consumers ... insurance plans can be found when using the open ... The national lookup system available to use this year ... for insurance based on general location and not from ...
(Date:8/30/2014)... Daily Gossip reveals in its review a program created by ... shows a unique formula to get inside a man’s mind ... the program goes beyond mere attraction and actually helps ladies ... that the program was created by dating expert Alex Carter, ... make a man feel emotionally addicted. , Learn more about ...
(Date:8/30/2014)... Albany, New York (PRWEB) August 30, 2014 ... a combination of Nutrition and Pharameuticals. Nutraceuticals is ... by extracting healthy ingredients from natural food sources. ... specific health benefits to the human body. Nutraceutical ... multivitamins, diet supplements, fortified foods and more. Although ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... August 30, 2014 Hundreds of Byetta ... continue to move forward in U.S. courts, Bernstein Liebhard ... PLC on July 31, 2014, Byetta and Bydureon (an ... product liability claims that allege the drugs caused pancreatitis, ... many of these claims are pending in a multidistrict ...
Breaking Medicine News(10 mins):Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 2Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 3Health News:A Granular Analysis of the Nutraceutical Ingredients Market by Transparency Market Research 4Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3
... A study of the development of autism in infants, ... autism to that of babies developing normally, has found that ... shared eye contact, smiling and communicative babbling are not ... apparent during the latter part of the first year of ...
... week,s issue of PLoS Medicine provides a substantial ... of health research. The authors of the paper have been ... health research guidelines published over the past few years, including ... for systematic reviews. The accurate reporting of a ...
... , , ... You,re hitting the gym four to five times a week. ... a time. But all those long, boring workouts do nothing to strengthen ... you,ll get old before your time. , (Photo: http://www.newscom.com/cgi-bin/prnh/20100215/FL54993 ) , ...
... Annals Readers Respond to USPSTF Mammography Guidelines An ... 17 article, "Screening for Breast Cancer: U.S. Preventive Services Task ... on February 15 at 5:00 p.m. ... Function, COPD Sound bites and b-roll footage available ...
... benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings ... a new study published online February 15 in the ... that the rate of new infections preventable by vaccination declines ... age typically do not progress to cervical intraepithelial neoplasia grade ...
... still inhale fumes, and lungs suffer, study finds , MONDAY, ... lungs by smoking pipes or cigars instead of cigarettes are ... smoke by any means is deleterious," said Dr. R. Graham ... Medical Center and lead author of a report in the ...
Cached Medicine News:Health News:Autism's earliest symptoms not evident in children under 6 months 2Health News:Autism's earliest symptoms not evident in children under 6 months 3Health News:Autism's earliest symptoms not evident in children under 6 months 4Health News:Is Your Exercise Routine Killing You? 2Health News:Is Your Exercise Routine Killing You? 3Health News:Embargoed News from Annals of Internal Medicine 2Health News:Embargoed News from Annals of Internal Medicine 3Health News:Embargoed News from Annals of Internal Medicine 4Health News:News brief: Benefit of HPV Vaccination, Frequent Screening for Women over 41 is Likely to be Low 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 2Health News:Cigars, Pipes No 'Healthy' Alternative to Cigarettes 3
... advanced system for laser therapy available today. The ... fiber handpiece that allows to perform linear scanning ... 20% of the energy reflected by the skin. ... special gel which optimizes the optical coupling between ...
... is a high power CO2 laser particularly ... possible with this device in rheumatology, dermatology, ... displays the selected fluence and performs a ... an internal power meter. Moreover, an ...
Smart Cryo is a powerful cool-air generator that provides intense localised skin cooling without any contact, thus guaranteeing a high degree of hygiene and an effective cooling action, indispensable...
Smartepil II is a laser particularly indicated for hair-removal where it has proved to be a valid instrument, even in the treatment of darker phototypes and telangiectasias of the face and legs....
Medicine Products: